DBV Technologies to Participate in Upcoming Investor Conferences
09 Maggio 2024 - 10:30PM
Montrouge, France, May 9, 2024
DBV Technologies to
Participate in Upcoming Investor Conferences
DBV Technologies (Euronext: DBV – ISIN:
FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage
biopharmaceutical company focused on treatment options for food
allergies and other immunologic conditions with significant unmet
medical need, today announced Daniel Tassé, Chief Executive
Officer, will deliver a company presentation at two investor
conferences in May.
Citizens JMP Life Sciences Conference –
May 13, 2024Format:
Fireside Chat
Time: 11:00am
ETLocation: Hilton Midtown
Hotel, New York, NY
H.C. Wainwright BioConnect Conference –
May 20, 2024Format:
Fireside Chat Time:
12:00pm
ET Location:
NASDAQ World Headquarters, New York, NY
A live webcast of each presentation will be
available on the Events page on the Investors section of the
Company's website www.dbv-technologies.com. A replay will also be
available for 90 days after each event.
About DBV TechnologiesDBV
Technologies is a clinical-stage biopharmaceutical company
developing treatment options for food allergies and other
immunologic conditions with significant unmet medical need. DBV is
currently focused on investigating the use of its proprietary
technology platform, Viaskin™, to address food allergies, which are
caused by a hypersensitive immune reaction and characterized by a
range of symptoms varying in severity from mild to life-threatening
anaphylaxis. Millions of people live with food allergies, including
young children. Through epicutaneous immunotherapy (EPIT™), the
Viaskin platform is designed to introduce microgram amounts of a
biologically active compound to the immune system through intact
skin. EPIT is a new class of non-invasive treatment that seeks to
modify an individual’s underlying allergy by re-educating the
immune system to become desensitized to allergen by leveraging the
skin’s immune tolerizing properties. DBV is committed to
transforming the care of food allergic people. The Company’s food
allergy programs include ongoing clinical trials of Viaskin Peanut
in peanut allergic toddlers (1 through 3 years of age) and children
(4 through 7 years of age).
DBV Technologies is headquartered in Montrouge,
France, with North American operations in Warren, NJ. The Company’s
ordinary shares are traded on segment B of Euronext Paris (Ticker:
DBV, ISIN code: FR0010417345) and the Company’s ADSs (each
representing one-half of one ordinary share) are traded on the
Nasdaq Global Select Market (Ticker: DBVT).
For more information, please visit
www.dbv-technologies.com and engage with us on X (formerly Twitter)
and LinkedIn.
Viaskin and EPIT are trademarks of DBV
Technologies.
Investor Contact Katie
MatthewsDBV Technologieskatie.matthews@dbv-technologies.com
Media ContactAurora KrauseDBV
Technologiesaurora.krause-ext@dbv-technologies.com
Grafico Azioni DBV Technologies (NASDAQ:DBVT)
Storico
Da Mar 2025 a Mar 2025
Grafico Azioni DBV Technologies (NASDAQ:DBVT)
Storico
Da Mar 2024 a Mar 2025
